Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACP1 | P24666 | 1/20 | 0.36 |
| ▸ | MAP2K4 | P45985 | 4/20 | 0.35 |
| ▸ | SSTR2 | P30874 | 3/20 | 0.35 |
| ▸ | CLK2 | P49760 | 2/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.35 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.35 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.35 |
| ▸ | MAPKAPK3 | Q16644 | 2/20 | 0.35 |
| ▸ | MAPK6 | Q16659 | 2/20 | 0.35 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
| ▸ | PAK4 | O96013 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3523725 | 0.79 | ACP1 (0.37) | ACP1CLK2DYRK1ACLK4DYRK1B | |
| SCHEMBL3523406 | 0.79 | PARP1 (0.42) | CLK2DYRK1ACLK4DYRK1BCHEK1 | |
| SCHEMBL3522801 | 0.79 | KCNH2 (0.51) | CLK4MAPK1RETKDM4ECYP1A2 | |
| SCHEMBL3521426 | 0.78 | PDE4A (0.41) | CLK2DYRK1ACLK4DYRK1BCHEK1 | |
| SCHEMBL3523499 | 0.77 | TRPV1 (0.36) | MAP2K4CLK2DYRK1ACLK4DYRK1B | |
| SCHEMBL6999757 | 0.77 | ALOX5 (0.44) | MAP2K4CLK2DYRK1ACLK4DYRK1B | |
| SCHEMBL3522377 | 0.77 | TDP1 (0.43) | CLK2DYRK1ACLK4DYRK1BMAPK1 | |
| SCHEMBL3522991 | 0.75 | TDP1 (0.45) | CLK4MAPK1KDM4ELMNACYP1A2 | |
| SCHEMBL3523428 | 0.74 | TDP1 (0.41) | CLK2DYRK1ACLK4DYRK1BMAPK1 | |
| SCHEMBL3527472 | 0.73 | LMNA (0.48) | MAP2K4MAPK1MAPKAPK2MAPKAPK3MAPK6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7652006-B2 | For therapy and prophylaxis of neuronal loss associated with stroke, global and focal ischemia, CNS trauma, hypoglycemia and surgery, for ameliorating neurodegenerative diseases | EURO-CELTIQUE S.A. (LU) | 2010-01-26 | — | — | US | disclosed |
| US-20040162299-A1 | Substituted quinazolines and analogs and the use thereof | EURO-CELTIQUE, S.A. | 2004-08-19 | — | — | US | disclosed |
| US-6765006-B2 | ANTAGONISTS OF AMINO-3-HYDROXY-5-METHYLISOXAZOLE-4-PROPIONIC ACID (AMPA) IONOTROPIC RECEPTORS; NEURODEGENERATIVE, ALZHEIMER'S, AND HUNTINGTON'S DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; SCHIZOPHRENIA, EXCITATORY AMINO ACID DEFICIENCY | EURO-CELTIQUE S.A. (LU) | 2004-07-20 | — | — | US | disclosed |
| EP-1066039-A4 | SUBSTITUTED QUINAZOLINES AND ANALOGS AND THE USE THEREOF | COCENSYS INC (US) | 2003-02-26 | — | — | EP | disclosed |
| US-20030033089-A1 | Substituted quinazolines and analogs and the use thereof | EURO-CELTIQUE S.A. | 2003-02-13 | — | — | US | disclosed |
| US-6465472-B1 | SUCH AS 1-(2-DIETHYLAMINOETHYL)-6,7-METHYLENEDIOXY-4-(3,4-METHYLENE -DIOXYPHENYL)QUINAZOLIN-2(1H)-ONE; AMPA IONOTROPIC RECEPTOR ANTAGONISTS; ANTICONVULSANTS, COGNITIVE ENHANCERS, PREVENTION OF NEURODEGENERATION | EURO-CELTIQUE S.A. (LU) | 2002-10-15 | — | — | US | disclosed |
| EP-1066039-A1 | SUBSTITUTED QUINAZOLINES AND ANALOGS AND THE USE THEREOF | Cocensys, Inc. (US) | 2001-01-10 | — | — | EP | disclosed |
| WO-1999044612-A1 | SUBSTITUTED QUINAZOLINES AND ANALOGS AND THE USE THEREOF | COCENSYS, INC. (US) | 1999-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162299-A1 | Substituted quinazolines and analogs and the use thereof | CHRNA7, CHRNA2, CHRNA10 | ACP1 4686/4885MAP2K4 2070/4885SSTR2 3138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.